Identification
Instrument name
APTORUM GROUP CL A
Symbol
APM
ISIN code
KYG6096M1069
LEI code
984500B8DA8D2D9BFA46
Exchange / Market
Euronext
Trading location
Paris
Products family
Stocks
ICB
20103010 Biotechnology
Website address
Operation
IPO date
Issue type
Direct listing

Company profile

Aptorum Group Limited specialises in the research and development of therapeutic products in the fields of neurology, infectious diseases, gastroenterology, oncology, and so on. At the end of 2019, the group had one product in phase I/II clinical development (SACT-1; neuroblastoma treatment) and 6 products in preclinical development (ALS-4, ALS-1, ALS-2, ALS-3, CLS-1 and DOI NLS-2).

Source: Cofisem - Last Update: 24 Jul 2020
Key Executives
Chairman and Chief Executive Officer Ian Huen
Chief Financial Officer Sabrina Khan
Director Research & Development Thomas Lee
Source: Cofisem - Last Update: 24 Jul 2020
Key figures
Millenium 2019 2018 2017
Net sales 477 342
Cost of sales 709 283
Payroll
Operating income -16,251 -9,223 -5,083
Income tax
Net income -17,963 -13,514 -2,286
Net consolidated income (Group share) -16,686 -13,243 -2,274
Fiscal year end 12.19 12.18 12.17
Length of fiscal year (month) 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 24 Jul 2020
Shareholder information
Ian Huen 62.29 %
CGY Investments Limited 14.77 %
Darren Lui 7.91 %
Isabel Huen Ng Sui Fong 6.98 %
Justin Wu 0.68 %
Source: Cofisem - Last Update: 17 Jul 2020